Human chymase expression in a mice induces mild hypertension with left ventricular hypertrophy

Hypertension Research

Volumn 26, Issue 9, 2003, Pages 759-768

  Koga, Takafumi ^d   Urata, Hidenori ^a   Inoue, Yukiko ^a   Hoshino, Takafumi ^d   Okamoto, Takehiro ^d   Matsunaga, Akira ^d   Suzuki, Misao ^b   Miyazaki, Junichi ^c   Ideishi, Munehito ^d   Arakawa, Kikuo ^d   Saku, Keijiro ^d  

^a Fukuoka University Chikushi Hospital   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cardiac hypertrophy; Chymase; Leukocytosis; Oligotrichia; Transgenic mouse

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ACTIN; CHYMASE; COMPLEMENTARY DNA; LIVER ENZYME; VALSARTAN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; AORTA; ARTICLE; BASEMENT MEMBRANE; BLOOD VESSEL; BRAIN TISSUE; CELL LINE; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENHANCER REGION; EXTRACELLULAR MATRIX; FEMALE; FETUS DEATH; GENE CONSTRUCT; GENE EXPRESSION; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; IN VIVO STUDY; LEUKOCYTOSIS; LIVER; LUNG PARENCHYMA; MALE; MOUSE; NEWBORN; NONHUMAN; OOCYTE; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; PROMOTER REGION; SKIN; TRANSGENE; TRANSGENIC MOUSE; VIRUS GENE; WEIGHT REDUCTION; WILD TYPE;

ANIMALS; CHYMASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, TRANSGENIC; PHENOTYPE; SERINE ENDOPEPTIDASES;

EID: 10744227689     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.759     Document Type: Article

References (43)

1. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M: Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62: 207-210.
2. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K: Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998; 32: 514-520.
3. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357.
4. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H: Selective conversion of big endothelins to tracheal smooth muscle-constricting 31 -amino acid-length endothelins by chymase from human mast cells. J Immunol 1997; 159: 1987-1992.
5. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H: Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system. Am J Physiol 1998; 275: H1307-1312.
6. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
7. Miyazaki M, Takai S: Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res 2001; 24: 189-193.
8. Ihara M, Urata H, Kinoshita A, et al: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399-1405.
9. Ihara M, Urata H, Shirai K, et al: High cardiac angiotensin-II-forming activity in infarcted and non-infarcted human myocardium. Cardiology 2000; 94: 247-253.
10. Jin D, Takai S, Yamada M, Sakaguchi M, Miyazaki M: Beneficial effects of cardiac chymase inhibition during the acute phase of myocardial infarction. Life Sci 2002; 71: 437-446.
11. Hoshino F, Urata H, Inoue Y, et al: Chymase inhibition improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol 2003; 41: S11-S18.
12. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K: Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002; 55: 870-876.
13. Takai S, Jin D, Nishimoto M, et al: Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001; 69: 1725-1732.
14. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS: Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-825.
15. Tunon de Lara JM, Okayama Y, McEuen AR, et al: Release and inactivation of interleukin-4 by mast cells. Ann N Y Acad Sci 1994; 725: 50-58.
16. Longley BJ, Tyrrell L, Ma Y, et al: Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci USA 1997; 94: 9017-9021.
17. Rubinstein I, Nadel JA, Graf PD, Caughey GH: Mast cell chymase potentiates histamine-induced wheal formation in the skin of ragweed-allergic dogs. J Clin Invest 1990; 86: 555-559.
18. He S, Peng Q, Walls AF: Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase: selective enhancement of eosinophil recruitment by histamine. J Immunol 1997; 159: 6216-6225.
19. Vartio T, Seppa H, Vaheri A: Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem 1981; 256: 471-477.
20. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J: Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-4696.
21. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF: Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem 1997; 272: 7127-7131.
22. Hoit BD, Shao Y, Kinoshita A, Gabel M, Husain A, Walsh RA: Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. J Clin Invest 1995; 95: 1519-1527.
23. Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A: Cloning of the gene and cDNA for human heart chymase. J Biol Chem 1991; 266: 17173-17179.
24. Miyazaki J, Takaki S, Araki K, et al: Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 1989; 79: 269-277.
25. Hoffmann S, Krause T, van Geel PP, et al: Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. J Mol Med 2001; 79: 601-608.
26. Shimano H, Yamada N, Shimada M, et al: Hepatic and renal expression of rat apolipoprotein E under control of the metallothionein promoter in transgenic mice. Biochim Biophys Acta 1991; 1090: 91-94.
27. Urata H, Khosla MC, Bumpus FM, Husain A: Evidence for extracellular, but not intracellular, generation of angiotensin II in the rat adrenal zona glomerulosa. Proc Natl Acad Sci USA 1988; 85: 8251-8255.
28. Ekins R: One-step, labeled-antibody assay for measuring free thyroxine. 1: assay development and validation. Clin Chem 1992; 38: 2355-2358.
29. Fukamizu A, Sugimura K, Takimoto E, et al: Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993; 268: 11617-11621.
30. Ju H, Gros R, You X, Tsang S, Husain M, Rabinovitch M: Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA 2001; 98: 7469-7474.
31. Rampart M, Williams TJ: Evidence that neutrophil accumulation induced by interleukin-1 requires both local protein biosynthesis and neutrophil CD18 antigen expression in vivo. Br J Pharmacol 1988; 94: 1143-1148.
32. Sullivan GW, Carper HT, Sullivan JA, Murata T, Mandell GL: Both recombinant interleukin-1 (beta) and purified human monocyte interleukin-1 prime human neutrophils for increased oxidative activity and promote neutrophil spreading. J Leukoc Biol 1989; 45: 389-395.
33. Harada E, Nakagawa O, Yoshimura M, et al: Effect of interleukin-1 beta on cardiac hypertrophy and production of natriuretic peptides in rat cardiocyte culture. J Mol Cell Cardiol 1999; 31: 1997-2006.
34. Urata H, Boehm KD, Philip A, et al: Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91: 1269-1281.
35. Sanz MI, Weg VB, Bolanowski MA, Nourshargh S: IL-1 is a potent inducer of eosinophil accumulation in rat skin: inhibition of response by a platelet-activating factor antagonist and an anti-human IL-8 antibody. J Immunol 1995; 154: 1364-1373.
36. Dularay B, Elson CJ, Clements-Jewery S, Damais C, Lando D: Recombinant human interleukin-1 beta primes human polymorphonuclear leukocytes for stimulus-induced myeloperoxidase release. J Leukoc Biol 1990; 47: 158-163.
37. Wolf G, Ziyadeh FN, Thaiss F, et al: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-1058.
38. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM: Angiotensin II induces monocyte chemoattractant protem-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998; 83: 952-959.
39. Maurer M, Paus R, Czarnetzki BM: Mast cells as modulators of hair follicle cycling. Exp Dermatol 1995; 4: 266-271.
40. Maurer M, Fischer E, Handjiski B, et al: Activated skin mast cells are involved in murine hair follicle regression (catagen). Lab Invest 1997; 77: 319-332.
41. Reed RJ, Clark WH, Mihm MC: The cutaneous mucinoses. Hum Pathol 1973; 4: 201-205.
42. Rook AH, Prystowsky MB, Cassin M, Boufal M, Lessin SR: Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy: clinical, molecular, and immunologic observations. Arch Dermatol 1991; 127: 1535-1540.
43. Lattanand A, Johnson WC: Male pattern alopecia a histopathologic and histochemical study. J Cutan Pathol 1975; 2: 58-70.